BioSpace News Archive

InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of preclinical data showing SP-3164’s activity in non-Hodgkin’s lymphoma (NHL) animal models.

Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides.

Spark Therapeutics and Neurochase, a company specializing in the development of scalable therapeutic strategies and enabling technology for direct delivery to the central nervous system (CNS), today announced a strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).

Inteleos, a non-profit global healthcare certification organization, today announced the appointment of Vera M. Zlidar and Neil Sahota to its board of directors effective January 1.

The U.S. Food and Drug Administration announced it is proposing a change from time-based deferrals to assessing blood donor eligibility using gender-inclusive, individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

A decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers.

Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene expression, is pleased to announce the launch of its website, the addition of Andrew Schiermeier, Ph.D to its Board of Directors and the establishment of its Scientific Advisory Board.

Prenatal exposure to perfluorononanoic acid (PFNA), a chemical sometimes found in food or drinking water, is associated with autism-related traits in children, according to a new study funded by the Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.